Protein Or Peptide Standard Or Control (e.g., Hemoglobin, Etc.) Patents (Class 436/15)
-
Patent number: 6720163Abstract: The invention concerns a method for the determination of alkaline phosphatase in a sample by optical measurement in which interference by free haemoglobin or blood substitutes is eliminated by means of certain wavelength combinations, a method for eliminating interference caused by free haemoglobin or blood substitutes in a determination of alkaline phosphatase and the use of certain wavelength combinations to eliminate interference by free haemoglobin or blood substitutes.Type: GrantFiled: April 6, 2001Date of Patent: April 13, 2004Assignee: Roche Diagnostics GmbHInventors: Ralph Weisheit, Wolfgang Treiber
-
Patent number: 6713275Abstract: The invention concerns a method for the determination of alkaline phosphatase in a sample by optical measurement which is characterized in that a main measurement wavelength of 450±10 nm in combination with the rate blank procedure is used to eliminate haemoglobin interference, a method for eliminating interference by free haemoglobin or blood substitutes and the use of the combination of a main measurement wavelength with the rate blank procedure to eliminate interference by free haemoglobin or blood substitutes in the determination of alkaline phosphatase.Type: GrantFiled: April 6, 2001Date of Patent: March 30, 2004Assignee: Roche Diagnostics GmbHInventors: Ralph Weisheit, Wolfgang Treiber
-
Publication number: 20040048386Abstract: A method of emulating with a cyanide-free lyse solution, the measurement of hemoglobin in whole blood using a cyanide-containing lyse solution. Such an illustrative method includes: a) combining a predetermined amount of the whole blood sample with a predetermined amount of a cyanide-free lyse solution to form a mixture, b) developing the mixture to a molar absorbtivity (&egr;) in the range of about 12.4 to 12.6 mM−1cm−1, and c) measuring a level of light absorbance of the mixture at a wavelength of about 540 nm. In one preferred illustrative embodiment, the cyanide-free lyse solution includes: a quaternary ammonium salt surfactant, an anionic surfactant, a hemoglobin binding agent selected from the group consisting of imidazole or hydroxylamine, and an aqueous medium. In one preferred embodiment, the molar absorbtivity is developed to a value of about 12.5 mM−1cm−1. That is to say to a level that is substantially identical to that of the prior art standard, cyanomethemoglobin.Type: ApplicationFiled: April 7, 2003Publication date: March 11, 2004Applicant: Streck Laboratories Inc.Inventor: Jiong Wu
-
Patent number: 6696304Abstract: A process, a test kit, calibration standards, and the method of preparing such standards as useful for the qualitative and/or quantitative determination of total solid phase- or microparticle-immobilized, amine-containing reactants such as proteins is provided. The operating principle of the invention is distinct from a classical immunoassay based on antibody-antigen immune interaction or from standard calorimetric proteins assays of soluble proteins and allows the detection of as low as attogram (10−18 gm) levels of total analyte per microparticle.Type: GrantFiled: February 24, 2000Date of Patent: February 24, 2004Assignee: Luminex CorporationInventor: Travis Parker Davies
-
Patent number: 6673629Abstract: A chromatography assay device and method for use with whole blood samples utilizing a red blood cell separating agent to aggregate red blood cells and permit plasma or serum to flow by capillary action and a neutralizing agent to neutralize any effects the red blood cell separating agent may have on the device and method.Type: GrantFiled: January 15, 1998Date of Patent: January 6, 2004Assignee: Abbott LaboratoriesInventors: Toru Yoshimura, Toshihiro Ogasawara, Michihiro Saito, John P. Groff
-
Patent number: 6660488Abstract: Discoveries are disclosed that show particular aspects of recombinant DNA technology can be used successfully to produce a hitherto unknown type of human Platelet-Derived Growth Factor (PDGF) receptor protein free of other PDGF receptors. These proteins can be produced from DNA segments in cells in various functional forms. These forms variously enable biochemical and functional studies of these novel receptors as well as production of antibodies. Means are described for determining the level of expression of genes for specific types of PDGF receptor proteins, for example, by measuring mRNA in cells with PDGF receptor type-specific DNA probes or by measuring antigen in biological samples with type-specific antibodies.Type: GrantFiled: January 25, 2001Date of Patent: December 9, 2003Assignee: The United States of America as represented by the Department of Health & Human ServicesInventors: Toshimitsu Matsui, Stuart A. Aaronson, Jacalyn H. Pierce
-
Patent number: 6637257Abstract: A method and device for performing fluid analysis by separating cells and/or particles from a fluid, such as a biological, vehicular or industrial fluid. The device is a micromachined filtering device comprising a substrate with through-thickness vias having approximately equal diameters that prevent passage through the substrate of a first material while permitting passage through the substrate of other materials having diametrical dimensions less than the diameter of the vias. Electrodes are located on a surface of the substrate between vias so that as the first material collects at the surface of the substrate, the electrodes become electrically connected to produce an output signal in some proportion to the amount of the first material collected. The device can incorporate multiple micromachined substrates, yielding an analysis system that produces an electrical output for each of a number of properties or parameters.Type: GrantFiled: October 31, 2002Date of Patent: October 28, 2003Assignee: Integrated Sensing SystemsInventor: Douglas Ray Sparks
-
Patent number: 6632676Abstract: A novel reagent system for use with automated and semi-automated hematology analyzers including an essentially isotonic blood diluting reagent, a blood cell lysing and hemoglobin conversion reagent, and a second lysing reagent for differentiating white blood cells into classes by size and functional characteristics. The diluent reagent enhances properties for counting and sizing blood specimens, while stabilizing cellular volume and cellular integrity for many hours. The blood cell lysing reagent removes red blood cells and enables subsequent enumeration of white blood cells and simultaneous determination of hemoglobin without use of the toxic cyanide anion. The third lysing reagent and a companion quenching differentiates blood cells into classes by size and functional characteristics, based on d.c. impedance volume, conductivity/opacity and light scatter measurements. The companion quenching reagent adjusts pH and conductivity of the final measurement solution to match the analyzer system requirements.Type: GrantFiled: September 24, 1999Date of Patent: October 14, 2003Assignee: Clinical Diagnostic SolutionsInventors: Harold Richardson Crews, James Harrison Carter, II, Ted Sena
-
Patent number: 6632675Abstract: Multi-analyte reference solutions having a stable partial pressure of oxygen (pO2) in zero headspace packaging and methods for preparing such solutions are disclosed. The solutions have long shelf and use lives when stored at room temperature and are packaged in laminated foil containers having low or no oxygen reactivity. Access devices are also disclosed.Type: GrantFiled: August 16, 2000Date of Patent: October 14, 2003Assignee: Bayer CorporationInventors: Dennis R. Conlon, Minna A. Rannikko, Kevin J. Sullivan, Robert B. Green
-
Patent number: 6627738Abstract: Nitrosylhemoglobin can be produced by introducing gaseous NO into an aqueous solution of hemoglobin. It has been demonstrated that nitrosylhemoglobin in aqueous solution can be converted to SNO-hemoglobin upon introduction of oxygen to the solution, as is postulated to occur in the lungs. Nitrosylhemoglobin can be used in methods to produce the physiological effects of NO, for example, to reduce vasoconstriction and to inhibit platelet aggregation.Type: GrantFiled: August 6, 1999Date of Patent: September 30, 2003Assignee: Duke UniversityInventors: Jonathan S. Stamler, Andrew J. Gow
-
Publication number: 20030157720Abstract: The invention relates to a protein standard comprising a collection of at least three polypeptides of different size and mass. The polypeptides can be from natural or recombinant sources or both. The protein standard can be used for simultaneously estimating both the size and mass of another protein or other proteins.Type: ApplicationFiled: February 6, 2002Publication date: August 21, 2003Applicant: Expression Technologies Inc.Inventor: Chuan Li
-
Publication number: 20030129754Abstract: The present invention provides a method of monitoring calibration of a spectrophotometric apparatus that comprises one or more than one calibration algorithm for one or more than one analyte. This method comprises measuring absorbance of a quality control material with the apparatus to obtain a measurement, where the quality control material exhibits an absorbance spectra characterized as having a negative slope for a continuous spectral segment from about 5 nm to about 400 nm in length, or a wavelength there between, and where the spectral segment includes a principal calibration wavelength for the one or more than one analyte. The method then involves calculating one or more than one concentration values from the measurement using the one or more than one calibration algorithms, followed by comparing the one or more than one concentration values with an assigned value given to the quality control material for each of the one or more than one analytes.Type: ApplicationFiled: March 7, 2003Publication date: July 10, 2003Inventor: James Samsoondar
-
Patent number: 6555382Abstract: The present invention provides an improved solution for staining proteins in and/or on a solid matrix or support. Typically, a protein-containing gel or membrane may be washed in a hot solution of water for about five minutes, stained in a hot solution of COOMASSIE brilliant blue dye in dilute aqueous mineral acid for about five minutes, and then rinsed in water. The washing and/or staining steps may be performed by placing the gel in a wash and/or staining solution, respectively, heating the solution in which the gel is placed to boiling in a microwave oven, and incubating the gel in the solution for about five minutes. The entire procedure can be performed in a little over ten minutes, which represents an enormous time savings over existing methods.Type: GrantFiled: August 3, 2001Date of Patent: April 29, 2003Inventor: Ewald M. Wondrak
-
Publication number: 20030068822Abstract: Methods of calibrating and validating the calibration of hemoglobin assays include the use of calibrators and/or controls that incorporate cross linked blood substitute. The calibrators and controls can be formulated into kits.Type: ApplicationFiled: September 28, 2001Publication date: April 10, 2003Inventors: Merrit Jacobs, Karen Warren, James E. Love
-
Publication number: 20030044988Abstract: An improved blood suspension media for hematological compositions, having particular utility with a red blood cell component for devices using electronic and optical means for blood determinations, and processes for using the suspension media. The suspension media finds particular utility in providing the hematology control product with a stable and consistent MCV and RDW for an extended product shelf life.Type: ApplicationFiled: July 27, 2001Publication date: March 6, 2003Inventors: Michael Elliott, Dana B. Jacobs, Nery Ortiz, Wayne Goldson, Penny Whitley, Theodore J. Gerula
-
Patent number: 6509192Abstract: A method of quality control to diagnose the cause of a malfunction of an instrument. The method uses measurements of the physical property of a sample to diagnose the cause of a malfunction of an instrument. The spatial position of a control product sample is analyzed. Alternatively, the spatial position of a statistically significant number of patient blood samples can be used. The method enables the monitoring of an instrument for problems associated with debris and noise caused by red cell lysis inefficiency; instrument reagents pump volume settings; instrument laser alignments; instrument gain settings; and flow noise caused by partial plugs, residual plugs or other flow problems. The method provides a more specific indication of the type and cause of an instrument malfunctioning than non specific flagging provided by prior art methods.Type: GrantFiled: January 22, 1997Date of Patent: January 21, 2003Assignee: Coulter International Corp.Inventor: Carole Young
-
Patent number: 6498038Abstract: Disclosed is a method for determining alcohol intake or alcohol induced liver damage in a subject by quantifying the content of sialic acid in apolipoprotein J (Apo J). In particular the present invention involves the steps of (a) providing a sample containing Apo J from a subject; (b) purifying the Apo J from the sample; (c) determining sialylation index, i.e., moles of sialic acid peer mole of Apo J in the sample; and (d) evaluating whether the sialylation index is an indication of alcohol intake or alcohol related liver damage recovery from alcohol addiction or alcohol relapse in the subject.Type: GrantFiled: January 13, 2000Date of Patent: December 24, 2002Assignee: Bioprobes, Inc.Inventors: Pradeep Ghosh, Raj Lakshman, Eric Anthony Hale
-
Patent number: 6482648Abstract: The present invention relates to methods for the production of a stable troponin preparation and its use as a calibrator and/or control in immunoassays. The formulation is prepared from mammalian, preferably bovine, heart tissue which provides a calibrator/control composition which remains stable over a long period of time.Type: GrantFiled: October 14, 1997Date of Patent: November 19, 2002Assignee: Bayer CorporationInventors: Margit Doth, Christoph Petry
-
Publication number: 20020146755Abstract: A quality control material composition or a standard material for clinical laboratory tests, containing recombinant human serum albumin prepared by recombinant technology as a base component.Type: ApplicationFiled: February 1, 2001Publication date: October 10, 2002Inventors: Toshiyuki Baba, Takashi Fukui, Yuzzo Hasegawa, Hisahide Hiura, Yahiro Uemura
-
Publication number: 20020127634Abstract: Method and compositions are provided for the determination of telomere length and telomerase activity, as well as the ability to inhibit telomerase activity in the treatment of proliferative diseases. Particularly, primers are elongated under conditions which minimize interference from other genomic sequences, so as to obtain accurate determinations of telomeric length or telomerase activity. In addition, compositions are provided for intracellular inhibition of telomerase activity and means are shown for slowing the loss of telomeric repeats in aging cells.Type: ApplicationFiled: June 5, 1995Publication date: September 12, 2002Inventors: MICHAEL D. WEST, JERRY SHAY, WOODRING WRIGHT, ELIZABETH H. BLACKBURN
-
Patent number: 6403377Abstract: Hematology control compositions and systems used to measure a plurality of parameters in a blood sample are provided. The hematology control compositions are particularly useful as a control for multi-parameter, automated instrument systems. The control compositions comprise a reticulocyte component, a white blood cell component, a red blood cell component, a nucleated red blood cell component, a platelet component and a reticulated platelet component. Methods of making and using the control compositions are also provided.Type: GrantFiled: August 21, 2001Date of Patent: June 11, 2002Assignee: Streck Laboratories, Inc.Inventors: Wayne L. Ryan, John Scholl
-
Patent number: 6362003Abstract: A method of quality control to diagnose the cause of a malfunction of an instrument. The method uses measurements of the physical property of a sample to diagnose the cause of a malfunction of an instrument. The spatial position of a control product sample is analyzed. Alternatively, the spatial position of a statistically significant number of patient blood samples can be used. The method enables the monitoring of an instrument for problems associated with debris and noise caused by red cell lysis inefficiency; instrument reagents pump volume settings; instrument laser alignments; instrument gain settings; and flow noise caused by partial plugs, residual plugs or other flow problems. The method provides a more specific indication of the type and cause of an instrument malfunctioning than non specific flagging provided by prior art methods.Type: GrantFiled: September 14, 1998Date of Patent: March 26, 2002Assignee: Coulter CorporationInventors: Carole Young, Michael Elliott, Nancy Naylor, Timothy J. Fischer
-
Patent number: 6350601Abstract: Disclosed is a stabilized enzyme composition for use in clinical examination, comprising: (a) an enzyme component comprising at least two enzymes selected from the group consisting of alkaline phosphatase, creatine kinase and alanine aminotransferase; (b) a stabilizer component comprising effective stabilizing amounts of an albumin, and at least one saccharide selected from the group consisting of trehalose and sorbitol; and (c) an aqueous medium having dissolved therein the components (a) and (b). The enzyme composition of the present invention is stable for a prolonged period of time not only under non-freeze refrigeration conditions, but also under freezing conditions or under conditions for non-freeze refrigeration after thawing of the frozen composition, as compared to the conventional enzymatic compositions.Type: GrantFiled: May 8, 1997Date of Patent: February 26, 2002Assignee: Asahi Kasei Kogyo Kabushiki KaishaInventors: Ryoji Aoki, Shigeru Ueda
-
Patent number: 6338967Abstract: Reagent composition and quantities used to prepare a simple, solid stable and reproducible protein assay and reproducible solventless protein assay standard. The method of preparing the protein assay and protein assay standards is also described. A solidifying agent such as a solid acid is added to the dye reagent solution prior to removal of solvent so as to produce a solid dye assay reagent.Type: GrantFiled: July 10, 1999Date of Patent: January 15, 2002Inventor: David Bickar
-
Publication number: 20010049146Abstract: The present invention relates to the use of sterol esters for the long-term stabilization of biological fluids, in particular even those which are obtained by lyophilization and subsequent reconstitution.Type: ApplicationFiled: October 29, 1999Publication date: December 6, 2001Applicant: Dade Behring Marburg, GmbHInventor: HARALD ALTHAUS
-
Patent number: 6319720Abstract: The present invention provides an improved method for staining proteins in and/or on a solid matrix or support. Typically, a protein-containing gel or membrane may be washed in a hot solution of water for about five minutes, stained in a hot solution of COOMASSIE brilliant blue dye in dilute aqueous mineral acid for about five minutes, and then rinsed in water. The washing and/or staining steps may be performed by placing the gel in a wash and/or staining solution, respectively, heating the solution in which the gel is placed to boiling in a microwave oven, and incubating the gel in the solution for about five minutes. The entire procedure can be performed in a little over ten minutes, which represents an enormous time savings over existing methods.Type: GrantFiled: October 13, 1999Date of Patent: November 20, 2001Inventor: Ewald M. Wondrak
-
Patent number: 6309888Abstract: A method having clinically sufficient degree of diagnostic accuracy for detecting the presence of coronary artery disease in a human patient from the general population and for distinguishing between the stages of the disease in that patient is disclosed. The stages are, first, the non-acute stage, which is either asymptomatic coronary artery disease or stable angina, second, the acute stage known as unstable angina, and, third, the acute stage known as acute myocardial infarction. The diseased state (as opposed to the non-diseased state) is indicated by the clinically significant presence of a first marker in a sample from the patient. The presence of one of the two acute stages, unstable angina or acute myocardial infarction, is indicated by the clinically significant presence of a second marker in a sample from the patient. The presence of the more severe acute stage known as acute myocardial infarction is indicated by the clinically significant presence of a third marker in a sample from the patient.Type: GrantFiled: September 4, 1998Date of Patent: October 30, 2001Assignee: Leuven Research & Development VZWInventors: Paul N. Holvoet, Désiré J. Collen
-
Method for improving the accuracy of the semi-quantitative determination of analyte in fluid samples
Patent number: 6306660Abstract: Disclosed is an improved method for determining the concentration of a first analyte in a fluid test sample as a function of a second analyte also present in the sample whose concentration in the fluid sample is clinically related to that of the first analyte. The method involves determining the concentration of the first analyte, and, if this concentration is outside of its useful analytical range, dividing this concentration by the normal concentration of the second analyte. This method of ratioing the concentrations of the first and second analyte is advantageous because accuracy is increased with fewer false positive and false negative results being reported.Type: GrantFiled: January 18, 2000Date of Patent: October 23, 2001Assignee: Bayer CorporationInventors: Koleen K. Messenger, Michael J. Pugia, Jane F. Wallace -
Patent number: 6294652Abstract: The invention provides Response regulator polypeptides and polynucleotides encoding Response regulator polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing Response regulator polypeptides to screen for antibacterial compounds.Type: GrantFiled: January 18, 2000Date of Patent: September 25, 2001Assignee: SmithKline Beecham CorporationInventors: Sanjoy Biswas, James Yigong Ge, David John Holmes, Karen A Ingraham, John Throup, Nicola Gail Wallis, Magdalena Zalacain
-
Patent number: 6287794Abstract: The present invention relates to novel compounds and pharmaceutical composition, their preparation, and their use, having a antithrombotic effect through reversible inhibition of activated blood coagulation factor VIIa “FVIIa”.Type: GrantFiled: September 14, 1999Date of Patent: September 11, 2001Assignee: Aventis Pharma Deutschland GmbHInventors: Pavel Safar, Alena Safarova, Peter Wildgoose
-
Patent number: 6284475Abstract: The present invention provides methods for diagnosing and/or monitoring thrombophilic disease in a patient that can result from the antiphospholipid antibody syndrome (aPL syndrome). The methods of the invention are premised on the inhibition of binding of an anticoagulant protein, annexin, preferably annexin-V, to phospholipids by antiphospholipid (aPL) antibodies in a patient blood sample.Type: GrantFiled: July 10, 1998Date of Patent: September 4, 2001Assignee: Mount Sinai School of Medicine of the City of New YorkInventor: Jacob H. Rand
-
Publication number: 20010006683Abstract: The present invention relates to stabilized compositions of troponin capable of serving as standard and/or control in immunoassays intended for assaying cardiac and/or skeletal troponin(s) in the blood serum or blood plasma of humans or animals. These stabilized compositions comprise, in aqueous solution, troponin I, troponin T and troponin C in the form of an I-T-C ternary complex.Type: ApplicationFiled: February 17, 1998Publication date: July 5, 2001Inventor: DENIS ROBERT MARIE RIOCHET
-
Patent number: 6251611Abstract: A method of determining the presence of chronic volume dependent hypertension is provided wherein a determination is made as to whether there has been a substantial reduction in phosphorylation of the blood-derived protein or renal proximal brush border membrane protein and if such reduction exists concluding that chronic volume dependent hypertension exists in a patient. The method may advantageously be practiced by employing blood serum or blood plasma as the body specimen containing the protein in determining whether a patient has chronic volume dependent hypertension, a cellular component of the blood, such as a blood-derived protein coming from the plasma membrane of lymphocytes. The method may include subsequent therapeutic patient treatment. Related diagnostic apparatus is also provided.Type: GrantFiled: September 26, 1997Date of Patent: June 26, 2001Assignee: Tulane University Medical CenterInventor: Jules B. Puschett
-
Patent number: 6241946Abstract: A method for preparing a solventless protein standard is disclosed in which a solventless dye indicator and a predetermined amount of solventless protein are placed in an appropriate receptacle such as the well of a multiwell plate. This results in a solventless protein standard in which the solventless protein and the solventless dye are contained within the same receptacle. When an appropriate solvent is added to the receptacle, the protein and dye react together to produce a color change which is detectable, and which can be used as a standard for a protein assay using that dye. Also claimed is the solventless protein assay standard produced by the process.Type: GrantFiled: February 10, 1998Date of Patent: June 5, 2001Inventor: David Bickar
-
Patent number: 6242417Abstract: The present invention relates to a hemoglobin compositions stabilized against the formation of aggregates. The present invention further relates to methods of making such hemoglobin compositions.Type: GrantFiled: April 5, 1995Date of Patent: June 5, 2001Assignee: Somatogen, Inc.Inventors: Michael J. Gerber, Douglas L. Looker, Bruce A. Kerwin
-
Patent number: 6190916Abstract: The present invention relates to stable compositions useful as primary standards and calibrators and controls comprising a cardiac troponin I (cTnI) such as native, recombinant, addition and deletion forms thereof, whether or not complexed with other troponin subunits such as TnC and/or TnT, in an inactivated human serum. The compositions are obtained by incubating troponin complexes with human serum. The compositions are characterized by an immunodetectability ratio of epitopes on the N-terminal segment to epitopes on the C-terminal segment substantially equivalent to that of pooled, fresh serum from acute myocardial infarction patients.Type: GrantFiled: June 29, 1999Date of Patent: February 20, 2001Assignee: Spectral Diagnostics, Inc.Inventors: Shigui Liu, Min Yuan Zhang, Qinwei Shi
-
Patent number: 6187531Abstract: This invention relates to the measurement of analytes in dried blood samples. It has been discovered by measuring the hemoglobin in the dissolved dried blood sample, an estimate of blood volume may be made and used to make a correction for blood volume. Thus, analytes such as cholesterol, PSA, and other blood analytes can be more accurately determined. The invention further describes a blood collection device and disk material on which blood is dried to provide superior results.Type: GrantFiled: January 11, 2000Date of Patent: February 13, 2001Assignee: Biosafe Medical Technologies, Inc.Inventor: Steven P. Tyrrell
-
Patent number: 6174728Abstract: A control or calibration standard for use with instruments for the optical measurement of the hemoglobin content in blood samples, features scattering particles or beads dispersed in aqueous electrolyte solution. To prevent sedimentation of the beads during storage, they have a mean diameter of <0.6 &mgr;m, preferably about 0.3 &mgr;m, and a volume concentration of <1%, preferably <0.3%. To prevent long term agglomeration, a non-ionic surfactant with an added antioxidant can be included in the formulation.Type: GrantFiled: April 3, 1998Date of Patent: January 16, 2001Assignee: AVL Medical Instruments AGInventors: Daniel Ben-David, Charles L. Laughinghouse, James K. Tusa, Werner Ziegler, Herbert Kroneis, Ewald Jöbstl
-
Patent number: 6136960Abstract: The present invention is directed to a method of determining the ratio of the concentration or amounts of two or more chemical compounds and/or biopolymers, or of the relative amounts of sub-populations of closely structurally related compounds, in a multi-component mixture, extract, system, and the like using an analytical physicochemical process. The method is based on distribution of the components of the mixture (system, extract, etc.) between two or more immiscible phases and the subsequent determination of the total amounts (concentrations) of biopolymers (chemical compounds) or of the amounts (concentrations) of one or more component(s) or sub-populations of the system in the phases. The ratio between these concentrations is defined therein as the partition coefficient. The partition coefficient is used as a measure of the ratio of the amounts of two or more biopolymers (chemical compounds) or their sub-populations in a multi-component mixture (extract, system, etc.Type: GrantFiled: August 18, 1998Date of Patent: October 24, 2000Assignees: Boris Y. Zaslavsky, Arnon ChaitInventors: Arnon Chait, Boris Y. Zaslavsky
-
Patent number: 6136607Abstract: Multi-analyte reference solutions having a stable partial pressure of oxygen (pO.sub.2) in zero headspace packaging and methods for preparing such solutions are disclosed. The solutions have long shelf and use lives when stored at room temperature and are packaged in laminated foil containers having low or no oxygen reactivity. Access devices are also disclosed.Type: GrantFiled: February 3, 1998Date of Patent: October 24, 2000Assignee: Bayer CorporationInventors: Dennis R. Conlon, Minna A. Rannikko, Kevin J. Sullivan, Robert B. Green
-
Patent number: 6043043Abstract: Disclosed is an improvement to the method of determining the concentration of a hemoglobin adduct in a blood sample by the steps of assaying the blood sample for the total amount of hemoglobin, assaying the blood sample for the hemoglobin adduct, and dividing the hemoglobin adduct concentration by the total hemoglobin concentration. The improvement involves normalizing the measurement of the hemoglobin adduct to the total amount of hemoglobin in the blood sample.Type: GrantFiled: June 18, 1993Date of Patent: March 28, 2000Assignee: Bayer CorporationInventor: Kin-Fai Yip
-
Patent number: 6040135Abstract: This invention relates to the measurement of analytes in dried blood samples. It has been discovered by measuring the hemoglobin in the dissolved dried blood sample, an estimate of blood volume may be made and used to make a correction for blood volume. Thus, analytes such as cholesterol, PSA, and other blood analytes can be more accurately determined. The invention further describes a blood collection device and disk material on which blood is dried to provide superior results.Type: GrantFiled: March 5, 1999Date of Patent: March 21, 2000Assignee: Biosafe Laboratories, Inc.Inventor: Steven P. Tyrrell
-
Patent number: 5958781Abstract: Cyanide-free reagents for the determination of hemoglobin and leukocytes present in a blood sample contain an aqueous solution of at least one quaternary ammonium salt, preferably selected from the group of alkyltrimethylammonium salts, alkyldimethylbenzylammonium salts or alkylpyridium salts consisting of tetradecyltrimethyl ammonium bromide (TTAB), dodecyltrimethyl ammonium chloride, cetyltrimethyl ammonium bromide, hexadecyltrimethyl ammonium bromide and benzalkonium chlorides, and hydroxylamine salts, especially hydrochloride, sulfate and phosphates and other acid salts. The method involves mixing the reagent with a diluent- diluted blood sample, presenting it to an absorbance spectrophotometer and measuring the resulting optical density as an indicator of hemoglobin concentration. This cyanide-free reagent could be used solely for hemoglobin determinations, or , it can also be used in leukocyte counting and sizing using hematology instrumentation.Type: GrantFiled: May 27, 1997Date of Patent: September 28, 1999Assignee: Abbott LaboratoriesInventors: Show-Chu Wong, Sylvia Khoo
-
Patent number: 5925533Abstract: A conjugate consisting of a sequence of the analyte and an antibody against one of the antibodies used in the test can be employed, in aqueous solution and in precisely known quantity, as a stable calibrator in a sandwich immunoassay for detecting the analyte.Type: GrantFiled: December 13, 1996Date of Patent: July 20, 1999Assignee: Bayer AktiengesellschaftInventors: Margit Doth, Christoph Petry, Nicole Petesch
-
Patent number: 5891730Abstract: Provided is a method of preparing dye-based reference materials useful for calibrating or qualifying instrument systems that are diagnostic spectroscopically for hemoglobin and CO-ox fractions. The dye-based reference materials are non-proteinaceous and may be interpreted by CO-oximeter instrument systems as providing a spectrum substantially equivalent to the spectrum of blood, particularly with regard to hemoglobin and hemoglobin CO-ox fractions. Dye-based reference materials may be formulated to provide CO-ox fractions approximating those seen in a clinical setting, including normal physiological CO-ox fractions. The dye-based reference materials may be combined with other ingredients thus making the materials useful as references for pH and blood gas instruments and/or electrolyte instruments in addition to CO-oximeter instrument systems.Type: GrantFiled: February 28, 1997Date of Patent: April 6, 1999Assignee: Chiron Diagnostics CorporationInventors: Jay J. Li, Justin E. Davey, David P. Swist, Liann Voo
-
Patent number: 5882934Abstract: A cyanide-free lytic reagent composition and method for measuring the total hemoglobin concentration in a blood sample, for counting the number of leukocytes and for deferential counting of leukocyte subpopulations are described. The cyanide-free lytic reagent composition cotains a quaternary ammonium salt or a pyridinium salt to lyse erythrocytes and release hemoglobin, and an organic ligand including triazole and its derivatives, tetrazole and its derivatives, alkaline metal salts of oxonic acid, melamine, aniline-2-sulfonic acid, quinaldic acid, 2-amino-1,3,4-thiadiazole, triazine and its derivatives, urazole, DL-pipecolinic acid, isonicotinamide, anthranilonitrile, 6-aza-2-thiothymine, 3-(2-thienyl)acrylic acid, benzoic acid and alkali metal and ammonium salts of benzoic acid, and pyrazine and its derivatives to form a stable chromogen with hemoglobin, and a salt to adjust conductivity of the reagent for impedance measurement.Type: GrantFiled: March 24, 1998Date of Patent: March 16, 1999Assignee: Coulter International Corp.Inventors: Yi Li, Carole Young
-
Patent number: 5866425Abstract: This invention pertains to a PT Assay Calibrator and a method of preparing a PT Assay Calibrator including a coagulation factor such as recombinant FVII or recombinant FVIIa that will allow preparation of PT calibration curves with values about 100% and which will give results analogous to those obtained using fresh normal plasma.Type: GrantFiled: January 16, 1996Date of Patent: February 2, 1999Assignee: Dade AGInventors: Barry J. Woodhams, Michael E. Burgess-Wilson
-
Patent number: 5849510Abstract: The invention provides compounds which specifically inhibit factor Xa activity. The compounds consist of the structure X.sub.1 -YIR-X.sub.2, wherein X.sub.1 is H, acyl, alkyl, acylalkyl, arylalkyl or one or more amino acids, and X.sub.2 is a modified C-terminal group, one or more carboxy-protecting groups or one or more amino acids or other substituent, and Y, I and R are tyrosine, isoleucine and arginine, respectively, or peptidomimetic or organic structures that possess the same functional activity as Y, I and R, respectively. In addition, the present invention provides a compound having the structure A1-A2-(A3).sub.m --B, where m is 0 or 1. A compound of the invention can be linear or cyclic and can be about 2 and 43 residues in length. A compound of the invention is characterized, in part, in that it exhibits a specific inhibition of factor Xa activity with a K.sub.i of .ltoreq.100 .mu.M, preferably .ltoreq.Type: GrantFiled: October 8, 1997Date of Patent: December 15, 1998Assignee: Selectide CorporationInventors: Fahad Al-Obeidi, Michal Lebl, James A. Ostrem, Pavel Safar, Alena Stierandova, Peter Strop, Armin Walser
-
Patent number: 5837461Abstract: A method of detecting cone-photoreceptor-based vision disorders is disclosed. In one embodiment, the method comprises the steps of examining the amino acid sequences of a patient's L or M photopigments and correlating the amino acid combinations associated with vision disorder.Type: GrantFiled: October 31, 1996Date of Patent: November 17, 1998Assignee: MCW Research FoundationInventors: Maureen E. Neitz, John F. Neitz
-
Patent number: 5817474Abstract: A method for determining three-dimensional structural information of a protein which involves producing the protein in a form substantially labeled with .sup.13 C of .sup.15 N or both substantially labeled with .sup.15 N and .sup.13 C and partially labeled with .sup.2 H and subjecting the protein to nuclear magnetic resonance spectroscopic analysis. The isotopically labeled protein is produced by a method which involves producing a substantially labeled microbial protein hydrolysate, subjecting the protein hydrolysate to cation exchange chromatography to produce a partially purified labeled amino acid mixture, subjecting the partially purified labeled amino acid mixture to anion exchange chromatography to produce a purified labeled amino mixture and supplementing the purified labeled amino acid mixture with isotopically labeled cysteine and optionally with isotopically labeled glutamine and asparagine.Type: GrantFiled: July 16, 1996Date of Patent: October 6, 1998Assignee: Martek Biosciences CorporationInventor: Jonathan Miles Brown